3 terminated. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow emvododstat: new trials by email Literature Review of emvododstat trials Research Report on emvododstat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19) PTC299, SOC, Placebo - Pneumonia, COVID-19 | Phase 2 / Phase 3 | Terminated | PTC Therapeutics | 189 | 2020-07-09 | 2023-06-26 |
| PTC299 for Treatment of Neurofibromatosis Type 2 PTC299 - Neurofibromatosis 2 | Phase 2 | Terminated | PTC Therapeutics | 11 | 2009-07-31 | 2019-04-12 |
| PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction - Kaposi's Sarcoma | Phase 1 / Phase 2 | Terminated | AIDS Malignancy Consortium | 17 | 2008-09-01 | 2018-06-06 |
AIDS-related Kaposi sarcoma (1) · COVID-19 (1) · Coronavirus Infections (1) · HIV Infections (1) · Neurofibromatoses (1) · Neurofibromatosis 2 (1) · Pneumonia (1) · Sarcoma, Kaposi (1)
PTC Therapeutics (2) · AIDS Malignancy Consortium (1)
United States (3) · Australia (1) · Belgium (1) · Brazil (1) · Colombia (1) · France (1) · Mexico (1) · Poland (1) · Portugal (1) · South Africa (1) · Spain (1)
Jay Barth, MD (1) · Quintus Ngumah, OD, PhD (1) · Susan E. Krown, MD (1)
U01CA121947 (1)